Author:
Chen Xiang,Yao JiaXi,Liu Li,Zheng WenZhong,Hu XiaoYi,Zhu YanJun,Wang Hang,Guo JianMing
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Reference28 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
https://doi.org/10.3322/caac.21442
.
2. Ljungberg B, Albiges L, Bensalah K, Bex A, Giles RH, Hora M et al. EAU guidelines on renal cell carcinoma. 2017.
http://uroweb.org/guideline/renal-cell-carcinoma/
. Accessed 06, Aug, 2017.
3. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9.
https://doi.org/10.1200/jco.2008.21.4809
.
4. Fox P, Hudson M, Brown C, Lord S, Gebski V, De Souza P, et al. Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer. 2013;109(1):147–53.
https://doi.org/10.1038/bjc.2013.300
.
5. Teishima J, Kobatake K, Shinmei S, Inoue S, Hayashi T, Ohara S, et al. The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. Urol Oncol. 2017;35(11):662.e1–e7.
https://doi.org/10.1016/j.urolonc.2017.07.008
.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献